ARTICLE | Deals
VC-backed Mosaic, Repertoire, Tessellate all gain new partners: Deals Report
With headlines dominated by Merck KGaA/Springworks deal, smaller companies make deals to advance programs
April 28, 2025 11:47 PM UTC
The $3.9 billion acquisition of Springworks Therapeutics Inc. (NASDAQ:SWTX) by Merck KGaA (Xetra:MRK) captured headlines Monday morning, but a handful of smaller deals also garnered attention in recent days.
Mosaic Therapeutics Ltd., a targeted oncology company in the portfolio of Syncona Ltd. (LSE:SYNC), is obtaining rights to a pair of clinical programs from the Astex Pharmaceuticals unit of Otsuka Pharmaceutical Co. Ltd. The venture-backed company will advance ERK1/ERK2 inhibitor ASTX029, which has shown antitumor activity in a Phase II trial, and MDM2 antagonist ASTX295, which has completed a Phase I trial. Mosaic said each has the potential to be used in combinations...